Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Tolerability of Different Cenvacibart Presentations in Healthy Participants
NCT07876505Phase 1Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2026
- Primary completion
- Mar 2027
01
Overview
Phase 1, randomised, open-label trial of cenvacibart (2 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Area under the concentration-time curve from time zero to the last quantifiable concentration at Day 57 and Maximum observed concentration at Day 57. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
cenvacibart
Beyond the preview
Go deeper on NCT07876505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876505.